Full Text View
Tabular View
No Study Results Posted
Related Studies
Zoledronate in Preventing Bone Loss Caused By Long-Term Androgen Deprivation Therapy in Patients With Stage III or Stage IV Prostate Cancer
This study is ongoing, but not recruiting participants.
Study NCT00058188   Information provided by National Cancer Institute (NCI)
First Received: April 7, 2003   Last Updated: May 9, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Osteoporosis
Prostate Cancer
Additional conditions recognized in this trial
Prostatic Neoplasms
More general conditions related to this trial
Bone Diseases
Bone Diseases, Metabolic
Genital Diseases, Male
Genital Neoplasms, Male
Musculoskeletal Diseases
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
cholecalciferol
calcium gluconate
zoledronic acid
Additional drug interventions recognized in this trial
Androgens
More general drug interventions related to this trial
Bone Density Conservation Agents
Growth Substances
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Vitamins
Sponsors listed in this trial
Robert H. Lurie Cancer Center
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services